Dry Eye Syndrome Treatment Market 2017 to Witness Growth Based On Rising Incidence of Economy till 2025

Dry eye syndrome keratoconjunctivitis sicca, is an ocular disease caused by the lack of tear fluid to lubricate the eyes, which leads to problems in vision, tear film instability, and discomfort causes potential damage to the ocular surface. Dry eye syndrome can also cause due to other ocular surface diseases such as ocular allergy and meibomian gland dysfunction. The ocular surface contains 7 components including lacrimal and accessory lacrimal apparatus. Any abnormalities in one of the ocular surface components may cause the dry eye syndrome. Dry eye syndrome is classified into two types namely, evaporative dry eye and pure aqueous deficiency dry eye. The common symptoms associated with dry eye syndrome include ocular irritation, hyperaemia, mucoid discharge, blurred vision, excessive tearing, ocular dryness, photophobia, and grittiness. Dry eye syndrome is measured by a thin strip of filter paper placed at the edge of the eye, called a Schirmer test to measure the amount of tears present in the eye.

The global dry eye syndrome treatment market is expected to grow at a significant CAGR due to rise in the geriatric population tear glands weaken due to aging and can’t produce sufficient tear fluid to maintain a lubricating film over the eyes and increase in the prevalence of dry eye syndrome. The increase in the prevalence of diabetes, vitamin A deficiency, lupus, thyroid disorders, and rheumatoid arthritis might fuel the dry eye syndrome treatment market. Moreover, increasing awareness among the population about diagnosis and treatment of dry eye syndrome, steady government support for medical research has allowed researchers to treat this condition more precisely and comprehensively, external stimuli such as laser eye surgery, and computer screen overuse are key factors also boosting the dry eye syndrome treatment market over the forecast period. However, expiration of blockbuster drug patents, the popularity of selfmedication by patients is the major restraints for the dry eye syndrome treatment market over the forecast period.

Dry eye syndrome treatment market segmented on the basis of treatment type, disease type, and distribution channel.

Get free sample of Global Dry Eye Syndrome Treatment  Market Report here – https://www.planetmarketreports.com/report-sample/dry-eye-syndrome-treatment-market-11051

Based on treatment type, dry eye syndrome treatment market has been segmented into the following:

  • Lubricant Eye Drops
  • PreservativeFree Drops
  • Oily Tear Eye Drops
  • Eye Ointments
  • Antiinflammatory Drugs
  • Corticosteroids
  • Tetracyclines Oral
  • Autologous Serum Eye Drops
  • Nutrition supplements

Based on disease type, dry eye syndrome treatment market has been segmented into the following:

  • Evaporative dry eye syndrome
  • Aqueous dry eye syndrome

Based on distribution channel, dry eye syndrome treatment market has been segmented into the following:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others

To enquire about the report more, click here – https://www.planetmarketreports.com/enquire-now/dry-eye-syndrome-treatment-market-11051

Global dry eye syndrome treatment market is in the developing stage owing to increase in the research and development activities by the competitors in the dry eye syndrome treatment market. The patents of various dry eye syndrome treatment drugs are in expiry stage, so various pharmaceutical companies are actively involved in the R&D of new drugs. Some of the key strategies followed by various pharmaceutical companies to increase revenue share in global dry eye syndrome treatment market including acquisitions & mergers, collaborations, and launching of new products. For instance, in July 2013, Novaliq GmbH won European approval for its lubricating, drugdelivering eye drop NovaTears, designed for over the counter treatment of dry eye syndrome. Similarly, in June 2015, Allergan plc, a pharmaceutical company acquired Oculeve Inc, a medical device company that focuses on new technologies for dry eye disease to improve market position in the dry eye syndrome treatment market. In addition, in January 2018, Novaliq announced the positive topline results of phase 2 clinical trial evaluating CyclASol in adults with moderate to severe dry eye disease. Moreover, in October 2015, Allergan plc launched artificial tear Refresh Optive gel drops to provide artificial tear option to relieve dry eye symptoms.

Geographically, the dry eye syndrome treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the dry eye syndrome treatment market due to high prevalence of lifestyle disorders which increase the chances of contracting dry eye syndrome, increase in the using medications such as antihistamines, pain relievers and antidepressants also increase the risk of dry eye syndrome in North America. Europe holds a dominant share in dry eye syndrome treatment market attributed to increase in the healthcare infrastructure, rise in the R&D activities, and increase in the usage of various medications which reduce the volume of tears produced in the eyes results in dry eye syndrome. Asia-Pacific is an emerging region in dry eye syndrome treatment market owing to increase in population majorly in India and China, strong government support in AsiaPacific region.

Some of the players in dry eye syndrome treatment market are Novartis AG Switzerland, Nicox France, Allergan U.S., Santen Pharmaceutical Co., Ltd. Japan, Otsuka Holdings Co., Ltd. Japan, Auven Therapeutics U.S., AFT Pharmaceuticals New Zealand, IMed Pharma, Inc. Canada, Sun Pharmaceuticals Industries Ltd. India, Mimetogen Pharmaceuticals U.S., and Novaliq GMBH Germany to name a few.

In March 2018, Novaliq inked an agreement with AFT Pharmaceuticals for the commercialization of NovaTears in New Zealand and Australia

In August 2017, Auven Therapeutics completed the enrollment in confirmatory phase 3 clinical trial of Seciera OTX101 for the treatment of dry eye syndrome treatment

In November 2015, Allergan plc inked a licensing agreement with Mimetogen Pharmaceuticals, for the development and commercialization of tavilermide MIMD3, a TrkA agonist used in the treatment of dry eye syndrome treatment.

To Browse Similar Reports @ https://www.planetmarketreports.com/category/pharmaceutical-and-healthcare

About Us: –

Planet Market Reports gives statistical surveying reports to businesses, people and associations with a goal of helping them in their decision-making process. We have huge database of market research reports & company profiles across globe.  We associated with global market research a publisher who has a wide range of research specialists & industry experts which provides you deeper penetration of market research industry.

We have statistical surveying reports from number of top publishers and update our reports collections on daily basis with most recent research data to furnish our customers with the moment online access to our database. With access to this database, our customers will be able to benefit from expert insights on worldwide businesses, items, and market patterns. We help you in your buy choice by mapping your data needs with our immense accumulation of reports.

Contact US:-

Name: Ronald James

Email-Id: ronald.james@planetmarketreports.com

US:  +1-716-2260907

UK: +447441952057

Organization: Planet Market Reports